ArticleJCI insight2016
PD-1
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The prognostic value of myeloid derived suppressor cell level in hepatocellular carcinoma: A systematic review and meta-analysis.PloS one · 2019Pooled it
- Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model.Journal for immunotherapy of cancer · 2022Trial
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.Journal of hepatology · 2020Trial
- Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.JCI insight · 2019Trial
- A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC?Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction.JHEP reports : innovation in hepatology · 2026Article
- Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2025Article
- The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma.Biomarker research · 2025Review
- PD1Cancer immunology, immunotherapy : CII · 2025Article
- Five-year complete remission of super-giant hepatocellular carcinoma with hepatectomy followed by sorafenib plus camrelizumab: A case report.World journal of gastrointestinal surgery · 2025Article
- Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC.Frontiers in immunology · 2025Article
- T-Cell Dynamics Predicts Prognosis of Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.International journal of molecular sciences · 2024Article
- Novel Computed-Tomography-Based Transformer Models for the Noninvasive Prediction of PD-1 in Pre-Operative Settings.Cancers · 2023Article
- Selective reprogramming of regulatory T cells in solid tumors can strongly enhance or inhibit tumor growth.Frontiers in immunology · 2023Article
- Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma.Frontiers in immunology · 2023Review
- A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study.BMC cancer · 2022Article
- Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.Oncoimmunology · 2022Review
- Increased PD-1Frontiers in oncology · 2022Article
- Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSorafenib is an oral antiangiogenic agent administered in advanced-stage hepatocellular carcinoma (HCC). Based on preclinical and human studies, we hypothesized that, in addition to its antiangiogenic properties, sorafenib may beneficially reduce the extent of the immunosuppressive network in HCC patients. To test this hypothesis, we examined whether alterations in the immunosuppressive burden of advanced-stage HCC patients correlated with clinical outcome.
methodsIn before and after sorafenib treatment, blood samples collected from 19 patients with advanced HCC, the frequency of PD-1
resultsOverall survival (OS) was significantly impacted by the reduction in the absolute number of both CD4
conclusionThis study is the first to our knowledge to demonstrate the potent immunomodulatory effects of sorafenib therapy on PD-1
trial registrationRegistration is not required for observational studies.
fundingThis study was supported by NCI Core Grant to RPCI (NIH P30 CA016056) and discretionary funds to Y. Thanavala.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.